NTII Neurobiological Technologies (MM)

EDGEWATER, N.J., May 15 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (NASDAQ:NTII) announced today that Vicki Higham, MSN, RN, has joined the company as Clinical Project Manager. Ms. Higham will manage the clinical operations program for Viprinex(TM) (ancrod), a reperfusion agent currently in Phase III development for acute ischemic stroke. Ms. Higham was the Study Delivery Leader for the U.S. portion of AstraZeneca's SAINT-II study for acute ischemic stroke. Warren W. Wasiewski, M.D., F.A.A.P., Vice President of Clinical Programs, said, "We are very pleased to have Ms. Higham who we expect will play a key role in NTI's Viprinex Phase III program. Ms. Higham brings twenty-three years of critical care nursing experience and almost ten years of clinical trial experience to NTI. This is a pivotal time in the company's history, and her expertise in the field of stroke clinical trials is an excellent addition to our already strong clinical team." Ms. Higham holds a Bachelor of Science degree in Nursing from Wilmington College and a Masters of Science degree as a Clinical Nurse Specialist in Adult Health from Widener University. About Neurobiological Technologies, Inc. NTI is a biotechnology company engaged in the business of acquiring and developing central nervous system related drug candidates. The Company is focused on therapies for neurological conditions that occur in connection with ischemic stroke and brain cancer. The Company's strategy is to in-license and develop later-stage drug candidates that target major medical needs and that can be rapidly commercialized. NTI's experienced management team oversees the human clinical trials necessary to establish preliminary evidence of efficacy. Forward-Looking Statements Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including: our need for additional capital, risks relating to the regulatory approval and commercialization of Viprinex, the inherent risk of failure in developing product candidates based on new technologies, the risks associated changes in our management team and other risks detailed from time to time in our Annual Report of Form 10-K and other filings with the Securities and Exchange Commission. Actual results may differ materially from those projected. These forward-looking statements represent our judgment as of the date of the release. We undertake no obligation to update these forward-looking statements. DATASOURCE: Neurobiological Technologies, Inc. CONTACT: Warren W. Wasiewski, M.D., F.A.A.P., Vice President of Clinical Programs of Neurobiological Technologies, Inc., +1-201-941-5000 Web site: http://www.ntii.com/

Copyright